Tool: DupCheckTool: DupCheck

www.DupCheck.org is a web-based tool to screen for duplicate patients in clinical trials within and across studies, sponsors and therapeutic areas. Please visit our "Tools" page for more information.


Project FlyerProject Flyer


Click here to download 
the NEWMEDS project flyer! 


ConsortiumConsortium
consortium teaser

QuicklinksQuicklinks
Project Office Project Office Annual PGB and WP Leads Meetings Annual PGB and WP Leads Meetings Project Governance Project Governance Funding Mechanisms Funding Mechanisms




  Members Area
Username:
Password:



EU
IMI | The Innovative Medicines Initiative
EFPIA | European Federation of Pharmaceutical Industries and Associations

F. Hoffmann-La Roche AG
Grenzacherstrasse 124
CH-4070
Basel,
Switzerland

Roche www.roche.com



Participant's Lead


Enrico Domenici
Molecular Biomarker Leader 
E-Mail to Enrico Domenici Contact  
 



Institute Presentation


Headquartered in Basel, Switzerland, Roche is one of the world’s leading innovation-driven healthcare groups. Its core businesses are pharmaceuticals and diagnostics. Roche is number one in the global diagnostics market. Roche employs roughly 65,000 people in 150 countries. The CNS group in Roche has expertise in the areas of Alzheimer’s disease, schizophrenia, depression, and imaging which spans from discovery where Roche scientists have made major advancements in identifying pathways involved in schizophrenia and depression to the clinic where innovative new first-in-class medications are being developed for these major psychiatric disorders. The CNS group at Roche is committed to contribute to the success of NEWMEDS by providing its expertise in several areas of interest including but not limited to: pharmaco MRI and preclinical studies where we will provide expertise in designing and performing experiments with animal models, PET ligand development where we will contribute to the development of novel radioligands through our expertise in several methods which include: synthesis of precursors, tritium radiolabeling, autoradiography, and in vivo binding. We will also contribute by providing genetic analysis including GWAS, CNV and transcriptional data and phenotypic characteristics from our clinical sample.


18 F. Hoffmann-La Roche AG